A new form of specific targeting cancer immunotherapy using anti-tumor monoclonal antibody-conjugated lymphokine-activated killer cells |
| |
| Authors: | H Shiraiwa T Sekine K Tobisu T Kakizoe K Koiso |
| |
| Affiliation: | National Cancer Center Research Institute, National Cancer Center Hospital, Tokyo. |
| |
| Abstract: | Cross-linking of effector T cells to target cancer cells augments their tumor lytic activities. Here we describe a new method of conjugating lymphokine-activated killer (LAK) cells with cancer-specific monoclonal antibody. The LAK cells were biotinylated, treated with avidin, and conjugated with biotinylated monoclonal antibody. These monoclonal antibody-conjugated LAK cells showed specifically enhanced killing activities against anti-tumor antibody-reactive cancer cells, and cold target cells specifically inhibited their activities. |
| |
| Keywords: | |
|
|
